[DOI] [PubMed] [Google Scholar] 82.Butiaeva LI, Slutzki T, Swick HE, Bourguignon C, Robins SC, Liu X
Mechanisms Behind GLP-1 Induced Weight Loss
[1] [2] The half-life of a medicationthe time required for the body to eliminate half of the drug's concentrationis the primary determinant of how long a GLP-1 receptor agonist remains in your system
The therapeutic benefits including appetite suppression, improved glycaemic control, and any weight loss effects will gradually diminish over the subsequent weeks as drug concentrations decline
Insulin resistance plays an important role in the pathophysiology of comorbid T2DM and depression and can be a trigger for dysregulation of insulin- and GLP-1-mediated signaling (both central and peripheral), neuroendocrine disorders (hypothalamicpituitaryadrenal system dysfunction and monoaminergic neurotransmission disorders), chronic low-intensity inflammation, oxidative stress, and disorders of the microbiota-gut-brain system, reducing the level of neurotrophic factors in the brain and changing synaptic plasticity
The Hims & Hers release comes amid a shortage of GLP-1s, as the demand for medications to treat obesity and diabetes outpaces the supply
